-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Initiates Coverage On Maze Therapeutics with Overweight Rating, Announces Price Target of $55

Benzinga·12/04/2025 13:39:08
Listen to the news
Wells Fargo analyst Sadia Rahman initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Overweight rating and announces Price Target of $55.